Plasma β-amyloid in Alzheimer's disease and vascular disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer’s disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Correlations between plasma and CSF Aβ and between plasma Aβ and [18F]flutemetamol SUVR. (A–C) Plasma (Simoa immunoassay) and CSF (Euroimmun immunoassay) Aβ42 and Aβ40 were measured in a cohort of 719 individuals (174 SCI, 214 MCI, 57 AD patients and 274 controls). (D–F) Neuocortical amyloid deposition was measured using [18F]flutemetamol PET in a cohort of 340 individuals (103 SCI, 112 MCI patients and 125 controls). Correlation coefficients (r) and p-values are from Pearson’s correlation analysis. AD, Alzheimer’s disease; CSF, cerebrospinal fluid; SCD, subjective cognitive decline; MCI, mild cognitive impairment; PET, positron emission tomography; SUVR, standardized uptake value ratio.](https://figures.cochat.ai/paper-figures/71bfab0f50314c6182d3ebedc2d5d0c6/plasma-amyloid-in-alzheimer-s-disease-and-vascular-disease-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“more recent studies have demonstrated that it correlates with brain Aβ and can differentiate patients with AD from healthy control participants.12,13”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many candidate blood biomarkers have failed in replication studies,7,8 but somewhat promising results have been seen for plasma tau, neurofilament light chain (NFL), and combinations of Aβ42 and Aβ40.9,10,11,12,13,14,15,16,17”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“a 65-year-old woman with only amyloid biomarkers but who is cognitively normal and has no neurodegeneration has a 10-year Alzheimer's disease risk of 2·5% and a man 2·3%, but the risk is higher with accompanying neurodegeneration (table 2 ).185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A model of lifetime risks of people who are amyloid positive without any other biomarkers finds it to be 8·4% for a 90-year-old woman who is cognitively normal at baseline, 23·5% for a 75-year-old woman and 29·3% for a 65-year-old woman.185”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [185]
Experimental — accuracy not yet measuredIn the citing paper
“Although previous studies have found associations between CSF and PET Aβ and plasma Aβ using different immunoassays,7,12,13,14,44,45 the present Elecsys assays produced among the best accuracies and they are the first fully automated assays to have these greater accuracies.”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationRissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationA New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L. O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Ader, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,797
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,043
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zlokovic, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 860
Research works printed but not linked: 1
- Janelidze, S. et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology (In press).
Cited by
Items 101–200 of 628
Planche, V., Bouteloup, V., Pellegrin, I., Mangin, J., Dubois, B., Ousset, P., Pasquier, F., Blanc, F., Paquet, C., Hanon, O., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201479 · Cited by 105
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Leuzy, A., Cullen, N. C., Mattsson, N., & Hansson, O. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000904 · Cited by 96
Self-citationThe relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
“The average concentration of circulating Aβ physiologically produced in rodent brains is estimated to be within the picomolar range (Cirrito et al., 2003, Janelidze et al., 2016).”
BackgroundSalivary Biomarkers for Alzheimer’s Disease and Related Disorders
Ashton, N. J., Ide, M., Zetterberg, H., & Blennow, K. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00168-1 · Cited by 89
Self-citationMolecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 102
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Thijssen, E. H., Verberk, I. M. W., Kindermans, J., Abramian, A., Vanbrabant, J., Ball, A. J., Pijnenburg, Y., Lemstra, A. W., van der Flier, W. M., Stoops, E., et al. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12285 · Cited by 86
Kuo, C.-Y., Stachiv, I., & Nikolai, T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17207475 · Cited by 104
Thijssen, E. H., Verberk, I. M. W., Vanbrabant, J., Koelewijn, A., Heijst, H., Scheltens, P., van der Flier, W. M., Vanderstichele, H., Stoops, E., & Teunissen, C. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-89004-x · Cited by 94
Aging biomarkers and the brain
Higgins‐Chen, A., Thrush, K., & Levine, M. E. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.01.003 · Cited by 94
Cullen, N. C., Janelidze, S., Mattsson‐Carlgren, N., Palmqvist, S., Bittner, T., Suridjan, I., Jethwa, A., Kollmorgen, G., Brum, W. S., Zetterberg, H., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12706 · Cited by 84
Self-citationPlasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
LonDownS Consortium, Startin, C. M., Ashton, N. J., Hamburg, S., Hithersay, R., Wiseman, F. K., Mok, K. Y., Hardy, J., Lleó, A., Lovestone, S., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0477-0 · Cited by 85
Self-citationPotential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment
Giau, V. V., Bagyinszky, E., & An, S. S. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174149 · Cited by 91
Song, L., Lachno, D. R., Hanlon, D., Shepro, A., Jeromin, A., Gemani, D., Talbot, J. A., Racke, M. M., Dage, J. L., & Dean, R. A. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0225-7 · Cited by 92
Self-citationA plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
Ashton, N. J., Nevado‐Holgado, A. J., Barber, I., Lynham, S., Gupta, V. B., Chatterjee, P., Goozee, K. G., Hone, E., Pedrini, S., Blennow, K., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau7220 · Cited by 88
Self-citationBody Fluid Biomarkers for Alzheimer’s Disease—An Up-To-Date Overview
Bălașa, A. F., Chircov, C., & Grumezescu, A. M. (2020) · Biomedicines · doi:10.3390/biomedicines8100421 · Cited by 92
Qu, Y., Ma, Y., Huang, Y., Ou, Y., Shen, X., Chen, S.-D., Dong, Q., Tan, L., & Yu, J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.007 · Cited by 94
Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study
van Arendonk, J., Neitzel, J., Steketee, R. M. E., van Assema, D. M. E., Vrooman, H. A., Segbers, M., Ikram, M. A., & Vernooij, M. W. (2022) · Brain · doi:10.1093/brain/awac354 · Cited by 89
Endothelial BACE1 Impairs Cerebral Small Vessels via Tight Junctions and eNOS
Zhou, H., Gao, F., Yang, X., Lin, T., Li, Z., Wang, Q., Yao, Y., Li, L., Ding, X., Shi, K., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.320183 · Cited by 88
Biomarkers for Alzheimer’s Disease
Guzman-Martinez, L., Maccioni, R. B., Farías, G. A., Fuentes, P., & Navarrete, L. P. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190517121140 · Cited by 87
Relevance of biomarkers across different neurodegenerative diseases
Ehrenberg, A. J., Khatun, A., Coomans, E., Betts, M. J., Capraro, F., Thijssen, E. H., Senkevich, K., Bharucha, T., Jafarpour, M., Young, P. N. E., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00601-w · Cited by 79
Self-citationLatest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà-Alomà, M., Suárez-Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 78
Tosun, D., Veitch, D., Aisen, P., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Bollinger, J., Ovod, V., Mawuenyega, K. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab008 · Cited by 79
Self-citationKorecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 88
Balistrieri, A., Makino, A., & Yuan, J. X. ‐. (2022) · Physiological Reviews · doi:10.1152/physrev.00030.2021 · Cited by 81
Benedet, A. L., Ashton, N. J., Pascoal, T. A., Leuzy, A., Mathotaarachchi, S. S., Kang, M. S., Therriault, J., Savard, M., Chamoun, M., Schöll, M., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.002 · Cited by 85
Self-citationUpdate on Biomarkers For Amyloid Pathology in Alzheimer’s Disease
Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 86
Self-citationShi, L., Westwood, S., Baird, A. L., Winchester, L., Dobricic, V., Kilpert, F., Hong, S., Franke, A., Hye, A., Ashton, N. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4951 · Cited by 74
Self-citationA novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid
Sweeney, M. D., Sagare, A. P., Pachicano, M., Harrington, M. G., Joe, E., Chui, H. C., Schneider, L. S. S., Montagne, A., Ringman, J. M., Fagan, A. M., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12061 · Cited by 74
Acoustofluidic multimodal diagnostic system for Alzheimer's disease
Hao, N., Wang, Z., Liu, P., Becker, R., Yang, S., Yang, K., Pei, Z., Zhang, P., Xia, J., Shen, L., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113730 · Cited by 77
Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer's disease
Brody, M., Agronin, M., Herskowitz, B., Bookheimer, S. Y., Small, G. W., Hitchinson, B., Ramdas, K. N., Wishard, T. J., McInerney, K., Vellas, B. J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12651 · Cited by 86
Yang, S., Chiu, M., Chen, T., & Horng, H. E. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0075-7 · Cited by 80
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J., Blennow, K., Johnson, K., Keeley, M., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P., & Vellas, B. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.14 · Cited by 71
Self-citationIncreasing the reproducibility of fluid biomarker studies in neurodegenerative studies
Mattsson-Carlgren, N., Palmqvist, S., Blennow, K., & Hansson, O. (2020) · Nature Communications · doi:10.1038/s41467-020-19957-6 · Cited by 72
Self-citationOptical nanomaterial-based detection of biomarkers in liquid biopsy
Kim, Y. J., Rho, W., Park, S.-M., & Jun, B. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01531-y · Cited by 86
Chatterjee, P., Zetterberg, H., Goozee, K. G., Lim, C. K., Jacobs, K. R., Ashton, N. J., Hye, A., Pedrini, S., Sohrabi, H. R., Shah, T. M., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1567-4 · Cited by 76
Self-citationA critical review: Recent advances in “digital” biomolecule detection with single copy sensitivity
Liu, H., & Yu, L. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112901 · Cited by 78
Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 78
Self-citationShi, Y., Lu, X., Zhang, L., Shu, H., Gu, L., Wang, Z., Gao, L., Zhu, J., Zhang, H., Zhou, D., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00095 · Cited by 71
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 78
Mai, T. D., Ferraro, D., Aboud, N., Renault, R., Serra, M., Tran, N. T., Viovy, J., Smadja, C., Descroix, S., & Taverna, M. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.09.003 · Cited by 72
Sharma, A., Pachauri, V., & Flora, S. J. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01247 · Cited by 67
Palmqvist, S., Insel, P. S., Zetterberg, H., Blennow, K., Brix, B., Stomrud, E., Initiative, T. A. D. N., study, T. S. B., Mattsson, N., & Hansson, O. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.014 · Cited by 65
Self-citationFan, Y., Han, W., Zhan, G., Li, S., Xiang, S., Zhu, B., Jiang, X., Yang, L., Luo, A., Hua, F., et al. (2019) · Aging · doi:10.18632/aging.101978 · Cited by 70
Microbiota impacts on chronic inflammation and metabolic syndrome - related cognitive dysfunction
Arnoriaga‐Rodríguez, M., & Fernández‐Real, J. M. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09537-5 · Cited by 77
Decreased plasma β‐amyloid in the Alzheimer's disease APP A 673 Tvariant carriers
Martiskainen, H., Herukka, S., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., & Hiltunen, M. (2017) · Annals of Neurology · doi:10.1002/ana.24969 · Cited by 64
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 81
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Developments in scalable strategies for detecting early markers of cognitive decline
Whelan, R., Barbey, F. M., Cominetti, M. R., Gillan, C. M., & Rosická, A. M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02237-w · Cited by 77
Bateman, R. J., Blennow, K., Doody, R. S., Hendrix, S. B., Lovestone, S., Salloway, S., Schindler, R. J., Weiner, M. W., Zetterberg, H., Aisen, P. S. S., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.21 · Cited by 65
Self-citationEffects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4
Masuoka, N., Yoshimine, C., Hori, M., Tanaka, M., Asada, T., Abe, K., & Hisatsune, T. (2019) · Nutrients · doi:10.3390/nu11071626 · Cited by 68
Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment
Chen, T., Lee, Y.-J., Lin, S.-Y., Chen, J.-P., Hu, C., Wang, P., & Cheng, I. H.-J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50315-9 · Cited by 83
Shahpasand‐Kroner, H., Klafki, H.-W., Bauer, C., Schuchhardt, J., Hüttenrauch, M., Stazi, M., Bouter, C., Wirths, O., Vogelgsang, J. S., & Wiltfang, J. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0448-x · Cited by 69
Abdullah, S. A., Najm, L., Ladouceur, L., Ebrahimi, F., Shakeri, A., Al‐Jabouri, N., Didar, T. F., & Dellinger, K. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302673 · Cited by 68
Applying fluid biomarkers to Alzheimer's disease
Zetterberg, H. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00007.2017 · Cited by 70
Self-citationCilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60
Shea, D. W., Colasurdo, E. A., Smith, A. S. T., Paschall, C. J., Jayadev, S., Keene, C. D., Galasko, D. R., Ko, A. L., Li, G., Peskind, E. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213157119 · Cited by 65
Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study
Hilal, S., Akoudad, S., van Duijn, C. M., Niessen, W. J., Verbeek, M. M., Vanderstichele, H., Stoops, E., Ikram, M. A., & Vernooij, M. W. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170458 · Cited by 59
Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer’s disease
Zhang, B., Zhang, C., Wang, Y., Chen, L., Qiao, Y., Wang, Y., Peng, D., & Initiative, A. D. N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1150510 · Cited by 62
Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
Yang, S., Chiu, M., Chen, T., Lin, C., Jeng, J., Tang, S., Lee, Y.-F., Yang, C., Liu, B.-H., Chen, H.-H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09009-3 · Cited by 65
Reddy, D. S., & Abeygunaratne, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911734 · Cited by 64
Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium
d’Uscio, L. V., He, T., & Katušić, Z. S. (2016) · Physiology · doi:10.1152/physiol.00021.2016 · Cited by 62
Verberk, I. M. W., Hendriksen, H. M. A., van Harten, A. C., Wesselman, L. M. P., Verfaillie, S. C. J., van den Bosch, K. A., Slot, R. E. R., Prins, N. D., Scheltens, P., Teunissen, C. E., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.007 · Cited by 57
Shen, X., Li, J., Wang, H., Li, H., Huang, Y., Yang, Y., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12104 · Cited by 57
Xu, L. Y., Wang, H., Xu, Y. F., Cui, W., Ni, W., Chen, M., Huang, H., Stewart, C., Li, L. X., Li, F., et al. (2022) · ACS Sensors · doi:10.1021/acssensors.2c00132 · Cited by 57
Sleep Deprivation Induced Plasma Amyloid-β Transport Disturbance in Healthy Young Adults
Meng, W., Zhao, B., Huo, K., Deng, Y., Shang, S., Liu, J., Li, Y., Ma, L., Jiang, Y., Dang, L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161213 · Cited by 62
Visual Dysfunction in Posterior Cortical Atrophy
da Silva, M. N. M., Millington, R. S., Bridge, H., James-Galton, M., & Plant, G. T. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00389 · Cited by 62
The AB255 Study Group, Pérez‐Grijalba, V., Arbizu, J., Romero, J., Prieto, E., Pesini, P., Sarasa, L., Guillén, F., Monleón, I., José, I. S., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0549-1 · Cited by 62
The Use of Antimicrobial and Antiviral Drugs in Alzheimer’s Disease
Iqbal, U., Zeng, E., & Pasinetti, G. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144920 · Cited by 57
Ding, M., Ding, S., Du, D., Wang, X., Hu, X., Guan, P., Lyu, Z., & Lin, Y. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117087 · Cited by 59
study, O. B. O. T. F., de Rojas, I., Romero, J., Rodríguez‐Gómez, O., Pesini, P., Sanabria, Á., Pérez‐Cordón, A., Ruiz, C. A., Hernández, I., Rosende‐Roca, M., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0444-1 · Cited by 59
Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Hardy-Sosa, A., León‐Arcia, K., Llibre‐Guerra, J. J., Berlanga‐Acosta, J., Baez, S. D. L. C., Guillén, G. E., & Valdes-Sosa, P. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.683689 · Cited by 60
Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals
Ferreira, P. C. L., Therriault, J., Tissot, C., Ferrari‐Souza, J. P., Benedet, A. L., Povala, G., Bellaver, B., Leffa, D. T., Brum, W. S., Lussier, F. Z., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13393 · Cited by 54
Self-citationObrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 56
Self-citationHampel, H. J., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B. J., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108081 · Cited by 55
Zeng, Q., Zhou, X., Yang, Y., Sun, Y., Wang, J., Zhai, C., Li, J., & Yu, H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120379119 · Cited by 54
van Gils, V., Rizzo, M., Côté, J., Viechtbauer, W., Fanelli, G., Salas‐Salvadó, J., Wimberley, T., Bulló, M., Fernández‐Aranda, F., Dalsgaard, S., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105604 · Cited by 57
Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Duff, E. P., Zetterberg, H., Heslegrave, A., Dehghan, A., Elliott, P., Allen, N. E., Runz, H., Laban, R., Veleva, E., Whelan, C. D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03426-4 · Cited by 66
Self-citationChatterjee, P., Elmi, M., Goozee, K. G., Shah, T. M., Sohrabi, H. R., Dias, C. B., Pedrini, S., Shen, K., Asih, P. R., Dave, P., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190533 · Cited by 53
Self-citationElevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction
Meakin, P. J., Coull, B. M., Tuharska, Z., McCaffery, C., Akoumianakis, I., Antoniades, C., Brown, J., Griffin, K. J., Platt, F., Ozber, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci122237 · Cited by 22
Dark, H. E., An, Y., Duggan, M. R., Joynes, C. M., Davatzikos, C. A., Erus, G., Lewis, A., Moghekar, A., Resnick, S. M., & Walker, K. A. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01459-y · Cited by 57
Tsai, C., Liang, C., Lee, J., Su, M., Lin, C., Chu, H., Tsai, C., Lin, G., Lin, Y., & Yang, F. (2019) · Journal of Clinical Medicine · doi:10.2139/ssrn.3464407 · Cited by 54
Veerabhadrappa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D. A., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678011 · Cited by 50
Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.401 · Cited by 50
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Montoya, J. A. G., Barrios‐Rodríguez, R., Santana, S., Sánchez‐Lara, I., Pardo, C. C., Fornieles‐Rubio, F., Montes, J., Ramírez, C. D., González‐Moles, M. Á., & Burgos, J. S. (2017) · Journal of Periodontology · doi:10.1902/jop.2017.170071 · Cited by 61
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 49
Self-citationBellomo, G., Bayoumy, S., Megaro, A., Toja, A., Nardi, G., Gaetani, L., Blujdea, E. R., Paoletti, F. P., Wojdała, A. L., Chiasserini, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13687 · Cited by 45
Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
Ashton, N. J., Suárez‐Calvet, M., Heslegrave, A., Hye, A., Razquín, C., Pástor, P., Sánchez‐Valle, R., Molinuevo, J. L., Visser, P. J., Blennow, K., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0545-5 · Cited by 45
Self-citationAdvances in amyloid beta oligomer detection applications in Alzheimer's disease
Jamerlan, A., An, S. S. A., & Hulme, J. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.115919 · Cited by 46
Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease
Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48
Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
Mielke, M. M., Anderson, M., Ashford, J. W., Jeromin, A., Lin, P., Rosen, A. C., Tyrone, J., VandeVrede, L. A., Willis, D. R., Hansson, O., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14150 · Cited by 50
Self-citationA head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Anastasi, F., Fernández‐Lebrero, A., Ashton, N. J., Ortiz‐Romero, P., Torres‐Torronteras, J., González‐Escalante, A., Milà‐Alomà, M., Contador, J., García‐Escobar, G., Manero-Borràs, R. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14609 · Cited by 55
Self-citationHenneghan, A. M., Haley, A. P., & Kesler, S. R. (2019) · Biological Research For Nursing · doi:10.1177/1099800419887230 · Cited by 51
A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease
Xu, C., Zhao, L., & Dong, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220673 · Cited by 48
Lue, L., Pai, M., Chen, T., Hu, C., Huang, L.-K., Lin, W., Wu, C., Jeng, J.-S., Blennow, K., Sabbagh, M. N., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00222 · Cited by 53
Self-citationPlasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau
Tsai, H.-H., Chen, Y.-F., Yen, R.-F., Lo, Y.-L., Yang, K.-C., Jeng, J.-S., Tsai, L.-K., & Chang, C.-F. (2021) · Brain · doi:10.1093/brain/awab332 · Cited by 44
Wu, X. Y., Xiao, Z., Yi, J., Ding, S., Gu, H., Wu, W., Luo, J., Liang, X., Zheng, L., Xu, H. Y., et al. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab192 · Cited by 41
Current research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis
Feng, L., Li, J., & Zhang, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101492 · Cited by 47
Advances in blood biomarkers for Alzheimer disease ( AD ): A review
Assfaw, A. D., Schindler, S. E., & Morris, J. C. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12870 · Cited by 47
Metadata
- Authors
- Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- National Hospital for Neurology and Neurosurgery (GB)
- Quanterix (United States) (US)
- University of Gothenburg (SE)
- Corresponding author
- Janelidze, Shorena
- Hansson, Oskar
- ORCID
- Venue
- Scientific Reports
- Published
- 2016-05-31
- Volume
- 6
- Issue
- 1
- Pages
- 26801-26801
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4886210
- OpenAlex
- W2414917913
- Cited by
- 626
- References
- 49
- Citations by year
- 2026: 53 · 2025: 59 · 2024: 75 · 2023: 77 · 2022: 80 · 2021: 75 · 2020: 73 · 2019: 59 · 2018: 45 · 2017: 22 · 2016: 6
- FWCI
- 39.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Australian Government
- Crafoordska Stiftelsen
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- plasma amyloid-beta, amyloid-beta 42, Aβ40, Alzheimer's disease, vascular disease, amyloid biomarkers, cerebrospinal fluid, white matter lesions, cerebral microbleeds, hypertension, diabetes mellitus, ischemic heart disease, mild cognitive impairment, subjective cognitive decline, amyloid PET, amyloid metabolism
- MeSH terms
- Aged, Alzheimer Disease, Female, Humans, Male, Vascular Diseases, Cohort Studies, Biomarkers, Amyloid beta-Peptides, Neocortex, Positron-Emission Tomography, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.